Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia

Oct. 1, 2020 12:00 UTC



SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Imago BioSciences, Inc. (“Imago”) a clinical-stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the first patient has been dosed in the first Imago-sponsored Phase 2b clinical trial of bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET).

“We are excited to start this study. There are many patients with essential thrombocythemia in need of alternatives to the current standards of care. Bomedemstat has the potential to serve as a new option for such patients,” said Hugh Young Rienhoff, Jr. MD, CEO, Imago BioSciences.

This Phase 2b multi-center, open-label study is designed to assess the safety, efficacy, and pharmacodynamics of bomedemstat, an oral inhibitor of the epigenetic enzyme lysine-specific demethylase 1 (LSD1) ( Identifier NCT04254978). Eligible patients aged 18 or older with ET who have failed at least one standard therapy and require treatment in order to lower their platelet count will be considered for participation in this study. Exploratory assessments include the serial measurement of mutant allele frequencies and changing plasma cytokine profiles. The trial is being conducted in the United States, the United Kingdom, Europe, New Zealand, and Australia.

About Bomedemstat (IMG-7289)

In addition to the ET study, bomedemstat is being evaluated in an open-label Phase 2 clinical trial for the treatment of advanced myelofibrosis (MF), a bone marrow cancer that interferes with the production of blood cells. MF patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor are eligible for the study of bomedemstat as monotherapy. The endpoints include spleen volume reduction and symptom improvement at 12 and 24 weeks of treatment. Preliminary results have been presented at meetings of the European Hematology Association and the American Society of Hematology.

Bomedemstat is an orally available small molecule discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents. Bomedemstat is an investigational agent currently being evaluated in ongoing clinical trials ( Identifier: NCT03136185, NCT04262141 and NCT04081220). Bomedemstat has FDA Orphan Drug and Fast Track Designation for the treatment of myelofibrosis and essential thrombocythemia, Orphan Drug Designation for treatment of acute myeloid leukemia and PRIME designation by the European Medicines Agency for the treatment of MF.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit, and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.



Steve Kunszabo
Canale Communications
(619) 849-5388


Source: Imago BioSciences, Inc.

Back to news